Researchers from the NEOSTAR Phase II trial reported that the addition of ipilimumab to a neoadjuvant (pre-surgical) combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic… read more.
When older adults with cancer take multiple medications — including ordinary drugs like blood pressure pills, supplements, or antacids — it can result in more toxic chemotherapy side… read more.
Giving colon cancer patients chemotherapy before surgery cuts their risk of the disease coming back, according to the results of a Cancer Research UK-funded clinical trial. The FOxTROT… read more.
Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022… read more.
A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma,… read more.
Addition of ibrutinib to standard chemotherapy for patients over 65 with previously untreated mantle cell lymphoma (MCL) has led to significantly improved progression-free survival, researchers reported on June… read more.
Here’s a scenario so common that it applies to nearly 92 percent of older adults with cancer: An individual comes in for treatment and reports taking several medications… read more.
University of Illinois Chicago researchers have developed a compound that may one day offer hope for pancreatic cancer treatment. A pre-clinical study of the experimental compound shows that… read more.
Merck Inc., announced that the FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic… read more.
– Bristol Myers Squibb announced three-year data from the CheckMate -743 trial that demonstrated a durable survival benefit with first-line treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared… read more.
Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained,… read more.
Too many “exhausted” T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukaemia (CLL) make it more challenging for chimeric antigen… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
